Plant Name: Larix decidua
Taxonomic Information:
Plant ID: NPO18680
Plant Latin Name: Larix decidua
Taxonomy Genus: Larix
Taxonomy Family: Pinaceae
Plant External Links:
NCBI TaxonomyDB:
71402
Plant-of-the-World-Online:
262420-1
Used in Medicines:
Country/Region:
ItalyTraditional Medicine System:
Medicinal Functions:
Anthelmintic; Antidote; Antirheumatic; Antiseptic; Astringent; Bach; Balsamic; Diuretic; Expectorant; Haemostatic; Laxative; Rubefacient; Stimulant; Vermifuge; Vulnerary
Geographical Distribution:
Ukraine; United States; Romania; Italy; Poland; Finland; Sweden; France; United Kingdom; Switzerland; Austria; Germany; Ireland; Belgium; Hungary; Norway
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| AMY1A;AMY1B;AMY1C; TDP1; P4HB; GFER; AKR1B1; POLB; | |
| KDM4E; | |
| F10; | |
| BACE1; | |
| FUT7; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | AMY1A;AMY1B;AMY1C | Salivary alpha-amylase | P04745 | CHEMBL2478 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004556; alpha-amylase activity | 3.028E-09 | 3.297E-05 | AMY1A, AMY1B, AMY1C |
| MF | Unclassified; | GO:0103025; alpha-amylase activity (releasing maltohexaose) | 3.028E-09 | 3.297E-05 | AMY1A, AMY1B, AMY1C |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.305E-06 | 2.651E-02 | CYP2C19, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0016491; oxidoreductase activity | 6.609E-06 | 2.651E-02 | AKR1B1, CYP2C19, CYP2D6, GFER, KDM4E, P4HB |
| BP | GO:0008152; metabolic process | GO:0005975; carbohydrate metabolic process | 1.310E-05 | 4.075E-02 | AKR1B1, AMY1A, AMY1B, AMY1C, FUT7 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00500 | Starch and sucrose metabolism | 7.405E-06 | 8.145E-05 | AMY1A, AMY1B, AMY1C |
| 09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 3.808E-06 | 8.145E-05 | AMY1A, AMY1B, AMY1C |
| 09150 Organismal Systems | 09154 Digestive system | hsa04970 | Salivary secretion | 2.993E-05 | 2.195E-04 | AMY1A, AMY1B, AMY1C |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.089E-04 | 5.989E-04 | FUT7, AMY1A, AMY1B, AMY1C, AKR1B1, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.039E-03 | 4.573E-03 | CYP2D6, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.707E-03 | 9.925E-03 | CYP2D6, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.012E-02 | 4.191E-02 | CYP2C19 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 2.080E-02 | 4.191E-02 | AKR1B1 |
| 09100 Metabolism | 09107 Glycan biosynthesis and metabolism | hsa00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 1.805E-02 | 4.191E-02 | FUT7 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 2.218E-02 | 4.191E-02 | AKR1B1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
| NA: NA | Christmas disease | NA | F10; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; |
| I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
| I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
| C00-D49: Neoplasms | Renal cancer | C64 | F10; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; |
| I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
| NA: NA | Haemophilia B | NA | F10; |
| I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
